Business
ENDRA Life Sciences Strengthens IP Portfolio with Issuance of Additional Patents for its Innovative Fatty Liver Imaging Probe
ANN ARBOR, MI / ACCESSWIRE / May 6, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), has
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"ANN ARBOR, MI / ACCESSWIRE / May 6, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), has recently been issued design patents D883487 and D883488 from the United States Patent and Trademark Office for its \"Thermoacoustic Imaging Probe\" and \"Thermoacoustic Imaging Probe With Outdents\".\"ENDRA's goal is to develop applications for our proprietary TAEUS technology in areas of high unmet clinical need, such as Non-Alcoholic Fatty Liver Disease (NAFLD) which affects over 1 billion people globally, and for which there are no practical diagnostic tools. The recently-issued ‘487 and 488' patents provide more robust intellectual property (IP) protection for our TAEUS platform in a key global market. In particular, the ‘487 patent protects the basic appearance of the FLIP probe, including the relevant combination of shapes and surface markings, while the ‘488 patent protects a user-friendly embodiment of the ‘487 patent,\" explained ENDRA's Chief Executive Officer, Francois Michelon. \"Our IP portfolio continues to grow and currently stands at 68 defined, filed, issued, and/or licensed assets, which will provide significant market protection as we enter the commercialization phase for our technology.\"About ENDRA Life Sciences Inc.ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS™), a ground-breaking technology that visualizes tissue like CT or MRI, but at 50X lower cost, at the point of patient care. TAEUS is designed to work in concert with one million ultrasound systems in global use today. TAEUS is initially focused on the measurement of fat in the liver, as a means to assess and monitor NAFLD and NASH, chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures. www.endrainc.comForward-Looking StatementsAll statements in this release that are not based on historical fact are \"forward-looking statements\" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe ou...